ArriVent Biopharma, Inc.
Clinical trials sponsored by ArriVent Biopharma, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing novel therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new drug tackle Hard-to-Treat gynecologic cancers? Results expected Aug 2027 (estimated)
-
Can a new drug tackle Hard-to-Treat gynecologic cancers?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…
Phase 1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare lung cancer: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…
Phase 3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug MRG007 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…
Phase 1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC